BIA Responds to Pfizer R&D Exit

The BioIndustry Association (BIA) has expressed its disappointment that Pfizer has announced its intention to exit its facility in Sandwich (announced 1st February), but points out that however grave this news, it does not change the fundamentals of the UK as a location for R&D.

Pfizer has made clear that this decision was part of a global programme of changes to R&D and not a reflection on the UK environment the Association said.

Nigel Gaymond, Chief Executive of the BIA, said: “The UK remains the second home next to the US for the pharmaceutical and biotech industry and indeed Pfizer’s commitment to their Cambridge, UK site – where they have announced there will be a new Pain and Sensory Disorders Unit – as their global hub in Europe demonstrates this.

“The BIA is committed to working with government to ensure the best possible environment for small bioscience companies to flourish. Recent initiatives such as the commitment to technology and innovation centres, the patent box and the Office for Life Sciences, will further strengthen the UK’s position as a primary location for hightech manufacturing and innovative research and development.

“Key to the government’s support of the sector going forward will be further detail on its growth strategy, which has highlighted life sciences as one of the UK’s engines for growth.

“More immediately critical for those Pfizer employees affected by the proposed exit are the discussions, which Government has committed to, exploring options for continuing research and development activities at the Sandwich facility. Government must now do all in its power to retain these talented and skilled individuals in the UK.

“The BIA is ready to play its part, particularly in facilitating interactions with smaller companies.”